Drug Discovery & DDS– category –
-
GLP-1 Receptor Agonists Expand Therapeutic Scope to MASH: Novo Nordisk’s Wegovy First FDA-Approved for MASH, Eli Lilly’s Oral Foundayo Launched
Drug Discovery Trends USA Overview The therapeutic scope of GLP-1 receptor agonists has expanded beyond diabetes and obesity to include cardiovascular risk, obstructive sleep apnea, chronic kidney disease, and by 2025, MASH (Metabolic Dy... -
FDA Approves, Clears Trials for Autism-Related Symptom Treatments: DeFloria’s AJA001 Oral Liquid Enters Phase 2, Generic Leucovorin Approved
Barchart.com (via DelveInsight) USA Overview The FDA has authorized Phase II clinical trials for DeFloria's AJA001 oral liquid, a plant-derived drug candidate for autism spectrum disorder (ASD)-related symptoms. Additionally, in March 20... -
Challenges in AI Drug Discovery Clinical Success Rates: Insilico’s Lenticelib First to Phase II, AlphaFold Accelerates Structural Biology
MDPI Switzerland Overview While AI drug discovery accelerates early-stage discovery, consistent improvement in late-stage clinical trial success rates remains a challenge. However, Insilico Medicine's lenticelib (NCT05938920) has become ... -
Patisiran and Inotersen Halt Polyneuropathy Progression in hATTR Amyloidosis; Next-Gen siRNA Vutrisiran Also FDA Approved
oneAMYLOIDOSISvoice USA Overview Patisiran (Onpattro) and inotersen (Tegsedi), TTR mRNA silencing therapies for hereditary ATTR amyloidosis (hATTR), have demonstrated the ability to halt the progression of polyneuropathy and even show im... -
Insilico Medicine’s AI Drug Discovery Accelerates: Lenticelib, First AI-Designed Target and Structure, Achieves IND in 18 Months and Enters Mid-Stage Clinical Trials
Forever.ai (Appears to be a scientific review/journal) Unknown Overview AI drug discovery is dramatically reducing early-stage discovery timelines from years to mere weeks or months, encompassing target selection, hit identification, lea... -
AI Significantly Reduces Drug Discovery Space: De Novo Protein Design and Bruker’s Data Platform Accelerate Innovation
Temple 8 Unknown Overview AI models are drastically reducing the biological exploration space in drug discovery by screening billions of virtual molecules in seconds, predicting binding affinities, and optimizing pharmacokinetic properti... -
Exponential Progression of Targeted Protein Degradation: First FDA-Approved PROTAC and Molecular Glues Unlock “Undruggable” Targets
MarinBio (Appears to be a scientific review/journal, affiliated with MarinBio, hence using their domain) USA Overview The field of targeted protein degradation (TPD) is rapidly evolving, enabling the degradation of previously "undruggabl... -
AI-Designed Drugs from DeepMind’s AlphaFold, Insilico, and Generate Biomedicines Advance to Mid-Late Stage Clinical Trials, Intensifying Drug Discovery Race
MedCity News USA Overview The AI drug discovery sector is intensifying as advanced AI-designed drugs are poised to deliver mid-to-late stage clinical trial results within the next two years, leveraging breakthroughs like DeepMind's Alpha... -
Arvinas/Pfizer’s PROTAC Drug Veppanu Receives Historic FDA Approval for ESR1-Mutant Advanced Breast Cancer, Demonstrating 43% PFS Risk Reduction
Cancer Discovery - AACR Journals USA Overview Arvinas and Pfizer's oral PROTAC drug, Veppanu, has received FDA approval for advanced breast cancer with ESR1 mutations, marking the first clinical validation of targeted protein degradation... -
Engineered Antibody Brainshuttle™ Technology Boosts Brain Drug Delivery of RNA-Based ASOs by Dual-Targeting TfR1 and CD98hc Receptors, Illuminating CNS Disease Treatment
EMJ Unknown Overview Antibody-based Brainshuttle™ technology has made significant strides in brain drug delivery for promising therapeutics like RNA-based antisense oligonucleotides (ASOs), which are otherwise unable to cross the blood-b...
